NDAORALTABLET
Approved
Jul 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ROBAXIN (methocarbamol) by Hikma is clinical pharmacology the mechanism of action of methocarbamol in humans has not been established, but may be due to general central nervous system (cns) depression. First approved in 1957.
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ROBAXIN (methocarbamol) is an oral muscle relaxant approved in 1957 that works via general CNS depression, though its exact mechanism on skeletal muscle remains unclear. It is used to treat muscle spasms and pain associated with acute musculoskeletal conditions. The drug has no direct action on muscle contractility, the motor end plate, or nerve fibers.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential downsizing of brand support teams and shift toward generic life-cycle management.
Mechanism of Action
CLINICAL PHARMACOLOGY The mechanism of action of methocarbamol in humans has not been established, but may be due to general central nervous system (CNS) depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber. Pharmacokinetics In…
Indications
Worked on ROBAXIN at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.